Navigation Links
Protagonist Therapeutics Names Richard S. Shames, M.D. as Chief Medical Officer
Date:9/10/2015

MILPITAS, Calif., Sept. 10, 2015 /PRNewswire/ -- Protagonist Therapeutics, Inc., a company developing novel, orally stable peptide therapeutics for gastrointestinal diseases and disorders, today announced the appointment of Richard S. Shames, M.D. as Chief Medical Officer. Dr. Shames, most recently Senior Vice President and CMO at Aldea Pharmaceuticals, joins Protagonist with over 25 years of experience in clinical medicine and the biotechnology/pharmaceutical industry.

"Richard Shames has a long track record of success in leadership positions in clinical drug development across multiple autoimmune and inflammatory diseases, which will serve Protagonist well as we initiate clinical trials of our lead oral peptide, PTG-100, for inflammatory bowel diseases," said Dinesh Patel, Ph.D., President and Chief Executive Officer of Protagonist. "His background includes oversight of the clinical development of novel small molecule and biologics programs at both clinical-stage biotechnology companies and global pharmaceutical firms. I am very pleased to welcome Richard to the Protagonist executive team."

"I am excited to join Protagonist Therapeutics as it advances its lead asset PTG-100 toward clinical trials," stated Dr. Shames. "There is a significant opportunity to bring targeted, orally stable therapies to patients who are affected by inflammatory bowel disease. I look forward to advancing our novel treatments into clinical development and potentially into therapeutic use."

Prior to joining Aldea, Dr. Shames was Distinguished Scientist, Clinical Research and Early Biologics Lead (Immunology) at Merck & Co., Inc. There he led the early stage development of novel biologics and biosimilar programs for over four years, including the clinical development of an anti-IL23p19 monoclonal antibody in psoriasis, currently in Phase 3 studies. Prior to joining Merck, Dr. Shames held positions of increasing responsibility at Facet Biotech (formerly PDL Biopharma) over the course of 10 years prior to that company's acquisition by Abbott, including management of Facet's immunology development pipeline, as Therapeutic Area Head of Immunology. Before joining the life sciences industry, Dr. Shames held full time clinical faculty positions in Pediatric Allergy and Clinical Immunology at Stanford University and the University of California, San Francisco Schools of Medicine. He received his M.D. degree from the University of California, Davis School of Medicine.

About Protagonist Therapeutics

Protagonist Therapeutics is a U.S.-incorporated biotechnology company engaged in the discovery and development of orally stable peptides as targeted therapy for inflammatory bowel diseases (IBD) and other gastrointestinal diseases and disorders. The company has an innovative and proprietary technology platform that enables it to develop potent and orally stable peptides against protein-protein interaction (PPI) targets that are otherwise undruggable by small molecules and therefore have historically been approached largely by injectable antibodies. Oral peptides may lead to a superior and safer choice for IBD patients, physicians, and payers by virtue of their better convenience and compliance, and potentially enhanced safety and efficacy in comparison to other therapeutic options. The company is nearing the completion of IND-enabling studies of an alpha-4-beta-7 integrin-specific oral peptide antagonist PTG-100, and has several other assets including an oral IL-23 receptor antagonist in different stages of research and pre-clinical development.

Protagonist is headquartered in Milpitas, California USA and is a spin-out from the University of Queensland's Institute of Molecular Biosciences (IMB).  The company has its pre-clinical and clinical operations in California, and discovery operations both in California and in Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.

Logo - http://photos.prnewswire.com/prnh/20130501/MM06086LOGO

 


'/>"/>
SOURCE Protagonist Therapeutics, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Protagonist Therapeutics Names David Liu Chief Scientific Officer
2. Protagonist Therapeutics Raises $14 Million in Series B Venture Financing
3. Protagonist Therapeutics Closes 2nd Tranche of $18 Million Series B for Advancing Development Candidate to Clinical Trials in 2015
4. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
5. Novelos Therapeutics Provides Product Pipeline Update
6. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
7. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
8. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
9. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
10. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
11. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... ... and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today ... Mandalay Bay Resort & Casino, Las Vegas on Oct. 15 – 19, 2019. ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... announced that FocalPoint Holdings, a privately-held investment and management firm specializing in ... than 8,000 ophthalmology and optometry providers Luma Health’s patient relationship technology to ...
(Date:10/8/2019)... ... ... ChoiceSpine LLC, a privately-held spinal device manufacturer based in Knoxville, TN, today announced ... and drive sales growth. , The following changes and new additions have been made ... to Senior Vice President of Strategic Partnerships; , Keith Clements hired ...
Breaking Medicine Technology:
(Date:10/8/2019)... ... 08, 2019 , ... What unique insights can three former Surgeons General of ... in the nation? That question will be answered at ICAA 2019: Shaping the Future ... The event will take place October 10-12, 2019, at the Gaylord Palms Resort and ...
(Date:10/8/2019)... ... October 08, 2019 , ... Dr. Amir HagShenas of Silicon Valley Smile Solutions ... relief from this common and treatable condition. Dr. HagShenas’ goal is to treat ... with uncomfortable symptoms, including tender and bleeding gums, and to prevent gum disease from ...
(Date:10/8/2019)... ... 08, 2019 , ... As a world-renowned expert using intravital ... with the University of Maryland Department of Veterinary Medicine, continues to make new ... and his lab have discovered a new pathway by which liver macrophages called ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... and pathologists, 4medica® President Gregg Church will inform conference attendees how ... reinventing labs orders management-by starting with the right, clean patient data. The single ...
(Date:10/8/2019)... ... October 08, 2019 , ... The University of California ... Health Awards 1st Round (Top Ten) Finalist in its Best Cardiovascular Digital Diagnostic ... that promote faster, better, more cost-effective healthcare by improving outcomes such as shorter ...
Breaking Medicine News(10 mins):